Search Results - "TENNER, Kathleen S"

Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines by Shah, Mithun Vinod, Wiktor, Anne E, Meyer, Reid G, Tenner, Kathleen S, Ballman, Karla V, Green, Stefan J, Sukov, William R, Ketterling, Rhett P, Perez, Edith A, Jenkins, Robert B

“…Purpose In 1998, the US Food and Drug Administration (FDA) approved human epidermal growth factor receptor 2 (HER2) testing guidelines to determine eligibility…”
Get full text

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer by Carter, Jodi M., Chumsri, Saranya, Hinerfeld, Douglas A., Ma, Yaohua, Wang, Xue, Zahrieh, David, Hillman, David W., Tenner, Kathleen S., Kachergus, Jennifer M., Brauer, Heather Ann, Warren, Sarah E., Henderson, David, Shi, Ji, Liu, Yi, Joensuu, Heikki, Lindman, Henrik, Leon-Ferre, Roberto A., Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna R., Couch, Fergus J., Knutson, Keith L., Goetz, Matthew P., Perez, Edith A., Thompson, E. Aubrey

“…The utility of spatial immunobiomarker quantitation in prognostication and therapeutic prediction is actively being investigated in triple-negative breast…”
Get full text

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial by PEREZ, Edith A, REINHOLZ, Monica M, DUECK, Amylou C, KETTERLING, Rhett P, INGLE, James N, LINGLE, Wilma L, KAUFMAN, Peter A, VISSCHER, Daniel W, JENKINS, Robert B, HILLMAN, David W, TENNER, Kathleen S, SCHFOEDER, Matthew J, DAVIDSON, Nancy E, MARTINO, Silvana, SLEDGE, George W, HARRIS, Lyndsay N, GRALOW, Julie R

“…We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy…”
Get full text

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer by Norton, Nadine, Fox, Nicholas, McCarl, Christie-Ann, Tenner, Kathleen S, Ballman, Karla, Erskine, Courtney L, Necela, Brian M, Northfelt, Donald, Tan, Winston W, Calfa, Carmen, Pegram, Mark, Colon-Otero, Gerardo, Perez, Edith A, Clynes, Raphael, Knutson, Keith L

“…Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy…”
Get full text

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial by Perez, Edith A, Thompson, E Aubrey, Ballman, Karla V, Anderson, S Keith, Asmann, Yan W, Kalari, Krishna R, Eckel-Passow, Jeanette E, Dueck, Amylou C, Tenner, Kathleen S, Jen, Jin, Fan, Jian-Bing, Geiger, Xochiquetzal J, McCullough, Ann E, Chen, Beiyun, Jenkins, Robert B, Sledge, George W, Winer, Eric P, Gralow, Julie R, Reinholz, Monica M

“…To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. DASL technology was…”
Get full text

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain by Knutson, Keith L, Clynes, Raphael, Shreeder, Barath, Yeramian, Patrick, Kemp, Kathleen P, Ballman, Karla, Tenner, Kathleen S, Erskine, Courtney L, Norton, Nadine, Northfelt, Donald, Tan, Winston, Calfa, Carmen, Pegram, Mark, Mittendorf, Elizabeth A, Perez, Edith A

“…The addition of trastuzumab to chemotherapy extends survival among patients with HER2(+) breast cancer. Prior work showed that trastuzumab and chemotherapy…”
Get full text

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance) by Haddad, Tufia C., He, Jun, O’Sullivan, Ciara C., Chen, Beiyun, Northfelt, Donald, Dueck, Amylou C., Ballman, Karla V., Tenner, Kathleen S., Linden, Hannah, Sparano, Joseph A., Hopkins, Judith O., De Silva, Chamath, Perez, Edith A., Haluska, Paul, Goetz, Matthew P.

“…Purpose To compare efficacy and safety of capecitabine and lapatinib with or without IMC-A12 (cituxumumab) in patients with HER2-positive metastatic breast…”
Get full text

Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study by Vargas, Carlos E., Thorpe, Cameron S., Dueck, Amylou C., Tenner, Kathleen S., Davidson, Nancy E., Martino, Silvana, Pisansky, Thomas M., Hwang, E. Shelley, Halyard, Michele Y., Pockaj, Barbara A., Perez, Edith A.

“…Background The goal of this study was to assess the impact of trastuzumab on locoregional failure. METHODS The analysis included 2763 patients with…”
Get full text

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria by Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Reinholz, Monica M., Tenner, Kathleen S., Davidson, Nancy E., Gralow, Julie, Harris, Lyndsay N., Kutteh, Leila A., Hillman, David W., Jenkins, Robert B., Chen, Beiyun

“…The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors…”
Get full text

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 by Moreno‐Aspitia, Alvaro, Hillman, David W., Dyar, Stephen H., Tenner, Kathleen S., Gralow, Julie, Kaufman, Peter A., Davidson, Nancy E., Lafky, Jacqueline M., Reinholz, Monica M., Lingle, Wilma L., Kutteh, Leila A., Carney, Walter P., Dueck, Amylou C., Perez, Edith A.

“…BACKGROUND Increased soluble human epidermal growth factor receptor 2 (sHER2) is an indicator of a poor prognosis in HER2‐positive metastatic breast cancer. In…”
Get full text

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial by Perez, Edith A, Ballman, Karla V, Mashadi-Hossein, Afshin, Tenner, Kathleen S, Kachergus, Jennifer M, Norton, Nadine, Necela, Brian M, Carr, Jennifer M, Ferree, Sean, Perou, Charles M, Baehner, Frederick, Cheang, Maggie Chon U, Thompson, E Aubrey

“…Genomic data from human epidermal growth factor receptor 2-positive (HER2+) tumors were analyzed to assess the association between intrinsic subtype and…”
Get full text

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer by Moreno-Aspitia, Alvaro, Dueck, Amylou C., Ghanem-Cañete, Ismael, Patel, Tejal, Dakhil, Shaker, Johnson, David, Franco, Sandra, Kahanic, Stephen, Colon-Otero, Gerardo, Tenner, Kathleen S., Rodeheffer, Richard, McCullough, Ann E., Jenkins, Robert B., Palmieri, Frances M., Northfelt, Donald, Perez, Edith A.

“…Lapatinib adds to the efficacy of trastuzumab in preclinical models and also in the neo-adjuvant setting. This study assesses the safety and feasibility of…”
Get full text

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial by Perez, Edith A., Ballman, Karla V., Mashadi-Hossein, Afshin, Tenner, Kathleen S., Kachergus, Jennifer M., Norton, Nadine, Necela, Brian M., Carr, Jennifer M., Ferree, Sean, Perou, Charles M., Baehner, Frederick, Cheang, Maggie Chon U., Thompson, E. Aubrey

“…Background: Genomic data from human epidermal growth factor receptor 2–positive (HER2+) tumors were analyzed to assess the association between intrinsic…”
Get full text

Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer by Chumsri, Saranya, Polley, Mei-Yin, Mathur, Pulkit, Reis, Aline, Tenner, Kathleen S., Weidner, Morgan, Advani, Pooja, Moreno-Aspitia, Alvaro, Perez, Edith A., Knutson, Keith L.

“…Abstract only 78 Background: Previous study demonstrated that activation of RAS/MAPK pathway is associated with reduced tumor infiltrating lymphocytes and poor…”
Get full text

Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs) by Leon-Ferre, Roberto Antonio, Carter, Jodi M, Hillman, David W., Tenner, Kathleen S., Zahrieh, David, Liu, Minetta C., Ingle, James N., Kalari, Krishna R., Visscher, Daniel W., Boughey, Judy Caroline, Couch, Fergus, Goetz, Matthew P.

“…Abstract only 548 Background: sTILs are a well-established prognostic and predictive biomarker in patients with operable TNBC receiving pre or postoperative…”
Get full text

Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the Randomized Clinical Trial: NCCTG N9831 (Alliance) Study by Vargas, Carlos E., Thorpe, Cameron S., Dueck, Amylou C., Tenner, Kathleen S., Davidson, Nancy E., Martino, Silvana, Pisansky, Thomas M., Hwang, E. Shelley, Halyard, Michele Y., Pockaj, Barbara A., Perez, Edith A.

Get full text

Abstract 5454: Peripheral blood biomarkers in Phase II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer by Chumsri, Saranya, Larson, Joseph J., Adams, Daniel L., Tenner, Kathleen S., Tang, Cha-Mei, Weidner, Morgan T., Arnold, Amanda N., Haley, Dana L., Advani, Pooja, Sideras, Kostandinos, Moreno-aspitia, Alvaro, Perez, Edith A., Knutson, Keith L.

“…Abstract Background: Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast…”
Get full text

Abstract P4-01-17: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer by Chumsri, Saranya, Larson, Joseph J., Tenner, Kathleen S., He, Jun, Polley, Mei-Yin, weidner, Morgan T., Arnold, Amanda N., Haley, Dana, Advani, Pooja, Sideras, Kostandinos, Moreno-Aspitia, Alvaro, Perez, Edith A., Knutson, Keith L.

“…Abstract Background: Previous studies demonstrated that activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor…”
Get full text

Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact by Shah, Mithun Vinod, Wiktor, Anne E., Meyer, Reid G., Tenner, Kathleen S., Ballman, Karla V., Ketterling, Rhett P., Perez, Edith A., Jenkins, Robert B.

“…Abstract only…”
Get full text

Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer by Knutson, Keith L., Clynes, Raphael A., Yeramian, Patrick, Kemp, Kathleen P., Shreeder, Barath, Ballman, Karla V., Tenner, Kathleen S., Erskine, Courtney L., Norton, Nadine, Northfelt, Donald W., Tan, Winston, Pegram, Mark D., Calfa, Carmen Julia, Mittendorf, Elizabeth Ann, Perez, Edith A.

“…Abstract only…”
Get full text